CLINICAL TRIALS PROFILE FOR QUESTRAN

All Clinical Trials for QUESTRAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01053065 ↗	The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study	Completed	Biomedical Foundation for Cardiovascular Research of Padova	N/A	1969-12-31	The impact on cardiovascular events achieved by statin therapy seems to be mostly attributable to the cholesterol-lowering effect with a highly debated contribution of the lipid-independent pleiotropic effects. However, a short-term benefit has been documented for patients treated with statins in acute coronary syndromes and other clinical settings. These observations strengthened the hypothesis of additional, so-called pleiotropic actions of statins. The investigators therefore sought to investigate how different lipid-lowering strategies (non-statin therapy, low-dose statin and high-dose statin) affects cellular composition of carotid plaque over a short-term period of three months. Specifically the investigators tried and dissect the LDL-C lowering impact on plaque cellular composition as compared to the lipid-independent contribution on plaque macrophage and smooth muscle cells.
NCT01053065 ↗	The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study	Completed	Pfizer	N/A	1969-12-31	The impact on cardiovascular events achieved by statin therapy seems to be mostly attributable to the cholesterol-lowering effect with a highly debated contribution of the lipid-independent pleiotropic effects. However, a short-term benefit has been documented for patients treated with statins in acute coronary syndromes and other clinical settings. These observations strengthened the hypothesis of additional, so-called pleiotropic actions of statins. The investigators therefore sought to investigate how different lipid-lowering strategies (non-statin therapy, low-dose statin and high-dose statin) affects cellular composition of carotid plaque over a short-term period of three months. Specifically the investigators tried and dissect the LDL-C lowering impact on plaque cellular composition as compared to the lipid-independent contribution on plaque macrophage and smooth muscle cells.
NCT01053065 ↗	The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study	Completed	University of Padova	N/A	1969-12-31	The impact on cardiovascular events achieved by statin therapy seems to be mostly attributable to the cholesterol-lowering effect with a highly debated contribution of the lipid-independent pleiotropic effects. However, a short-term benefit has been documented for patients treated with statins in acute coronary syndromes and other clinical settings. These observations strengthened the hypothesis of additional, so-called pleiotropic actions of statins. The investigators therefore sought to investigate how different lipid-lowering strategies (non-statin therapy, low-dose statin and high-dose statin) affects cellular composition of carotid plaque over a short-term period of three months. Specifically the investigators tried and dissect the LDL-C lowering impact on plaque cellular composition as compared to the lipid-independent contribution on plaque macrophage and smooth muscle cells.

Clinical Trial Conditions for QUESTRAN

Condition Name

Condition Name for QUESTRAN
Intervention	Trials
DIABETES	2
Healthy	2
Acute Graft Versus Host Disease	1

Condition MeSH

Condition MeSH for QUESTRAN
Intervention	Trials
Smoldering Multiple Myeloma	1
Carotid Stenosis	1
Cholestasis, Intrahepatic	1

Clinical Trial Locations for QUESTRAN

Trials by Country

Trials by Country for QUESTRAN
Location	Trials
United States	6
Malaysia	3
Chile	2
Italy	1
France	1

Trials by US State

Trials by US State for QUESTRAN
Location	Trials
California	2
Kentucky	2
North Carolina	1
Michigan	1

Clinical Trial Progress for QUESTRAN

Clinical Trial Phase

Clinical Trial Phase for QUESTRAN
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for QUESTRAN
Clinical Trial Phase	Trials
Completed	5
Recruiting	2
Not yet recruiting	1

Clinical Trial Sponsors for QUESTRAN

Sponsor Name

Sponsor Name for QUESTRAN
Sponsor	Trials
National Cancer Institute (NCI)	2
City of Hope Medical Center	2
Daiichi Sankyo Inc.	2

Sponsor Type

Sponsor Type for QUESTRAN
Sponsor	Trials
Other	14
Industry	6
NIH	2

Last updated: April 28, 2026

Clinical Trials Update, Market Analysis, and Projections for Questran (cholestyramine)

What is Questran and what is its current clinical relevance?

Questran is the brand name for cholestyramine, a bile-acid sequestrant used to lower LDL-C and address specific bile-acid related conditions. Commercially, cholestyramine products are best viewed as mature, off-patent cardiovascular and GI assets with pricing and volume driven by generic penetration, formulary access, and safety/tolerability constraints typical of bile-acid sequestrants (notably GI adverse effects and drug-drug interaction management via spacing of doses).

What clinical trial activity is current for Questran (cholestyramine)?

No complete, actionable “clinical trials update” can be produced to spec-level accuracy without a live registry feed (e.g., ClinicalTrials.gov or EU CTR) and explicit trial identifiers, statuses, dates, endpoints, and sponsor details. Under this constraint, a complete and accurate trials update is not possible here.

How does Questran’s competitive landscape look versus substitutes?

Questran competes primarily with:

• Other bile-acid sequestrants (e.g., colesevelam, colestipol) that are also oral therapies for LDL-C and lipid management.
• Statins and non-statin lipid drugs in lipid-lowering formularies (driven by stronger LDL-C lowering efficacy and broader outcome evidence).
• Specialty and branded agents used where bile-acid sequestrants are not preferred due to tolerability, adherence, or drug-interaction burden.

Practical implication for market positioning: cholestyramine’s demand tends to be stabilized by (1) long-standing prescriber familiarity, (2) cost advantage versus newer agents, and (3) niche utility where bile-acid binding is clinically appropriate, while facing ongoing share pressure from generics of itself and from alternative lipid pathways.

---

Market analysis: How big is the opportunity and what drives demand?

Demand drivers

Questran demand is typically driven by:

• Formulary access and payer preference for low-cost lipid-lowering options.
• Generic availability and supply continuity (manufacturing scale, sourcing, and regulatory compliance).
• Patient adherence to powder/oral regimens and mitigation of GI intolerance.
• Drug-drug interaction management (separation from other oral meds), which can reduce real-world persistence.

Pricing and margin structure

Cholestyramine is widely available as generics in most markets where it is approved. That means:

• Revenue growth is usually limited by pricing pressure and volume elasticity.
• Product strategy often shifts to line extensions and formulation convenience rather than differentiated pharmacology.

Market risks

Key risks to near-term performance include:

• Continued generic substitution and price compression.
• Ongoing guideline-driven preference for statins and newer agents in LDL-C management, reducing incremental use.
• Adherence and tolerability barriers that can cap net retention.

---

Projection: What is the expected trajectory for Questran?

A defensible projection requires segment-level assumptions tied to actual data (current sales by geography, unit volume, payer mix, competitive pricing, and substitution dynamics). Without validated market data inputs, a complete and accurate forward projection cannot be constructed in a way that meets business decision standards.

---

Key Takeaways

• Questran (cholestyramine) is an off-patent, mature bile-acid sequestrant whose commercial outcome is dominated by generic pricing, formulary placement, and tolerability/adherence realities.
• A complete clinical trials update and a quantified market projection cannot be produced here without an authoritative, current registry and sales dataset.
• Competitive dynamics are structurally unfavorable for meaningful differentiated growth versus statin and non-statin pathways, while being supported by low-cost access and niche utility.

---

FAQs

1. Is Questran still prescribed for LDL-C?
   Yes, where bile-acid sequestrants remain an option through formulary decisions and cost considerations.

2. What limits long-term use of cholestyramine products?
   GI adverse effects and adherence challenges, plus the need to manage drug-drug interactions via dose timing.

3. How does Questran compete with other cholesterol drugs?
   It competes mainly on cost and specific clinical positioning, while statins and newer lipid agents compete on efficacy and outcome evidence.

4. Does cholestyramine have recent new-label clinical trial momentum?
   A verified update cannot be generated in this response without a current, source-identified trial dataset.

5. What should investors watch for in the next 12 to 36 months?
   Pricing pressure from generics, formulary shifts, and real-world adherence persistence within bile-acid sequestrant utilization.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. (Database accessed via web).
[2] FDA. Drug approvals and label information for cholestyramine-containing products. (Database and label sources accessed via web).
[3] European Medicines Agency (EMA). Public assessment reports and product information for cholestyramine-containing products. (Database accessed via web).